Stem Cell Therapy Found Safe and Promising in Treating Parkinson's Disease, Landmark Trials Show
Email :
Stem cell therapy has emerged as a safe and potentially game-changing treatment for Parkinson's disease, according to the results of two major clinical trials published in the journal Nature.
The independent studies, conducted by research teams in Japan and the United States, demonstrate that stem cell-derived therapies can replenish dopamine-producing neurons in the brain — a critical factor in addressing the underlying cause of Parkinson's disease.
🧠 A New Approach to a Complex Disease
Parkinson's disease is a progressive neurodegenerative disorder marked by the loss of neurons that produce dopamine, a key neurotransmitter responsible for motor control. While current medications like ʟ-dopa offer temporary relief, they often lose effectiveness over time and cause side effects such as involuntary movements (dyskinesia).
The two new studies suggest that replacing damaged neurons with healthy, dopamine-producing cells derived from stem cells could offer a more sustainable and less intrusive solution.
🇯🇵 Japan Trial: No Major Side Effects, Promising Improvements
The first Phase I/II clinical trial, led by Kyoto University researchers, involved seven patients aged 50–69. These individuals received transplants of dopaminergic progenitor cells — derived from human induced pluripotent stem cells (iPSCs) — into both sides of their brains.
After 24 months of monitoring, no serious adverse events were reported. The transplanted cells successfully produced dopamine without forming tumors or growing uncontrollably — two major safety concerns in stem cell therapy.
Motor symptoms improved in four of the six patients who completed the efficacy evaluation without medication, and in five when standard Parkinson's medications were administered.
🇺🇸 US Trial: Stem Cells Show Strong Safety Profile
The second Phase I trial, conducted by Memorial Sloan Kettering Cancer Center in the US, tested a stem cell product known as bemdaneprocel, derived from human embryonic stem cells. Twelve patients with a median age of 67 underwent surgical transplantation of the cells into the putamen, a key area in the brain affected by Parkinson's.
Participants were divided into low-dose (five patients) and high-dose (seven patients) groups. Over 18 months, the therapy was well tolerated with no severe side effects or dyskinesia. Both groups also experienced some motor function improvement.
🧬 What's Next?
Despite the small sample sizes, both studies mark a critical step toward establishing stem cell therapy as a viable treatment for Parkinson's disease. Researchers emphasize the need for larger trials to further assess long-term benefits and confirm efficacy.
'This is an important step toward making cell therapy a standard treatment for Parkinson's,' the researchers stated. 'But larger studies will be essential to fully establish its clinical potential.'
These findings renew hope for millions living with Parkinson's and signal a shift toward regenerative medicine as a future standard of care.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Syyaha
15-06-2025
- Syyaha
The 5th International Neuroscience Summit for the Middle East, Africa and Russia (MEANS) is being held in Dubai.
The International Neurology Conference for the Middle East, Africa and Russia kicked off in Dubai, in cooperation with AbbVie, the global biopharmaceutical research and development company, with the participation of an elite group of international and national speakers and in the presence of several consultants, specialist physicians, researchers, professors and neurology experts from Gulf countries, Saudi Arabia, Egypt and Russia, in addition to several international, regional and local medical associations. The conference included several scientific lectures that discuss the latest research and treatment methods for many neurological diseases such as Parkinson's disease, migraine and post-stroke spasticity. Dr. Abdulrazzaq Al-Bilali, Headache Specialist and Head of the Saudi Headache Chapter, Saudi Neurology Society, commended the continuous efforts of the organizers of this major conference and its success for the fifth consecutive year. Dr. Abdulrazzaq emphasized that scientific research is the cornerstone of progress in the field of neurology. He explained that headache is a health problem that significantly impacts people's lives and daily activities, and that significant developments have occurred in diagnostic methods and disease management. He emphasized that the future of patient care lies in innovation and evidence-based knowledge. For his part, Dr. Suhail Al Rukun, consultant neurology, President of Emirates neurology Society in the United Arab Emirates, praised the large turnout at the conference, which included valuable medical discussions, workshops, and a review of the latest recommendations from clinical trials and research in this sector, in addition to presenting the best methods used in the management of patients with neurological diseases. Dr. Suhail added that this prominent scientific event is a good opportunity to exchange experiences and keep up with the latest developments in the neurology field. Organizing this summit for the fifth consecutive year embodies the ongoing commitment to enhancing medical knowledge and achieving the best treatment outcomes for patients. These initiatives help improve the quality of healthcare and open new horizons for improving patients' lives. Mohammad Aboubakr, Vice President and General Manager of AbbVie's Middle East, Africa & Russia region, commended the launch of the fifth Neurology Summit, which highlighted the latest emerging scientific and medical developments. He emphasized that organizing the summit reflects AbbVie's commitment to enhancing scientific training and research programs and providing a high level of medical care to serve society members by providing what helps improve their quality of life. The company seeks to help make a real difference in patients' lives, as well as its commitment to raising awareness and health education for patients, and on the other hand, its focus on the fields of education, training and scientific research
Daily Tribune
12-06-2025
- Daily Tribune
Writer first to die under Italy fast-track assisted suicide law
AFP | Rome A writer suffering from Parkinson's disease has become the first to die through medically assisted suicide under a fast-track regional law in Italy, campaigners said yesterday. Daniele Pieroni died at home on May 17, three months after the new legislation was passed by regional authorities in Tuscany, the pro-euthanasia Luca Coscioni Association said. The Italian Constitutional Court ruled in September 2019 that assisted suicide was allowed for patients in certain circumstances. But the national parliament has yet to adopt any legislation, which means that obtaining permission to die is difficult and can take years. In February, Tuscany -- ruled by the centre left -- became the first of Italy's 20 regions to set out its own rules streamlining and speeding up the request process. Prime Minister Giorgia Meloni's right-wing coalition is broadly against euthanasia and is challenging the Tuscan law in court. But any decision on that will come too late to affect Pieroni's choice. Born in 1961, the writer had been suffering from Parkinson's disease since 2008 and was forced to use a feeding tube for 21 hours a day, the Luca Coscioni Association said in a statement. 'The lethal drug was prepared at his home, which Daniele self-administered' in the presence of doctors and his family, the statement added. It has called on other regions in the Catholic-majority country to follow Tuscany's lead. 'Too many people continue to suffer or emigrate to die with dignity,' said the association. 'We invite all regions to act to guarantee freedom and respect for people's wishes.' Helping someone take their own life is technically illegal in Italy, punishable with between five and 12 years behind bars. But the Constitutional Court made an exception for those facing an incurable illness causing 'intolerable' physical or psychological suffering, where they are kept alive by life-support treatments but remain capable of making 'free and informed decisions'.
Daily Tribune
12-06-2025
- Daily Tribune
New T-Rex ancestor discovered in drawers of Mongolian institute
AFP | Paris Misidentified bones that languished in the drawers of a Mongolian institute for 50 years belong to a new species of tyrannosaur that rewrites the family history of the mighty T-Rex, scientists said yesterday. This slender ancestor of the massive Tyrannosauru s Rex was around four metres (13 feet) long and weighed three quarters of a tonne, according to a new study in the journal Nature. 'It would have been the size of a very large horse,' study co-author Darla Zelenitsky of Canada's University of Calgary told AFP. 1970s The fossils were first dug up in southeastern Mongolia in the early 1970s but at the time were identified as belonging to a different tyrannosaur, Alectrosaurus. For half a century, the fossils sat in the drawers at the Institute of Paleontology of the Mongolian Academy of Sciences in the capital Ulaanbaatar. Then PhD student Jared Voris, who was on a trip to Mongolia, started looking through the drawers and noticed something was wrong, Zelenitsky said. It turned out the fossils were well-preserved, partial skeletons of two different individuals of a completely new species. 'It is quite possible that discoveries like this are sitting in other museums that just have not been recognised,' Zelenitsky added. 'Messy' family history They named the new species Khankhuuluu mongoliensis, which roughly means the dragon prince of Mongolia because it is smaller than the 'king' T-Rex. Zelenitsky said the discovery 'helped us clarify a lot about the family history of the tyrannosaur group because it was really messy previously'. The T-Rex represented the end of the family line. It was the apex predator in North America until 66 million years ago, when an asteroid bigger than Mount Everest slammed into the Gulf of Mexico. Three quarters of life on Earth was wiped out, including all the dinosaurs that did not evolve into birds. Around 20 million years earlier, Khankhuuluu -- or another closely related family member -- is now believed to have migrated from Asia to North America using the land bridge that once connected Siberia and Alaska. North America This led to tyrannosaurs evolving across North America. Then one of these species is thought to have crossed back over to Asia, where two tyrannosaur subgroups emerged. One was much smaller, weighing under a tonne, and was nicknamed Pinocchio rex for its long snout. The other subgroup was huge and included behemoths like the Tarbosaurus, which was only a little smaller than the T-rex. One of the gigantic dinosaurs then left Asia again for North America, eventually giving rise to the T-Rex, which dominated for just two million years -- until the asteroid struck.
